ARQT compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

ARQTArcutis Biotherapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

ARQTArcutis Biotherapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARQT

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.3%▼−20.70%×1.68

Q2 FY26±10.2%▼−2.47%×0.25

Q1 FY26±13.1%▲+5.78%×0.44

Q3 FY25±15.7%▲+27.04%×1.72

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedARQT realized, solidLLY realized, hatchedOne scale, both sides: full bar = 28%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

ARQTArcutis Biotherapeutics, Inc.

25.55▼−5.38%· post 25.56

Mkt cap$3.2BRevenue$144MQ3 FY26Revenue$376MFY25

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

ARQTArcutis Biotherapeutics, Inc.

LLYELI Lilly & Co

25.55▼−5.38%post 25.56

Price

1,360.90▼−0.28%post 1,358.90

$3.2B

Mkt cap

$1.2T

Q3 FY26$144M

Revenue

$24.4BQ3 FY26

FY25$376M

Revenue

$65.2BFY25

ARQT25.55▼−5.38%vsLLY1,360.90▼−0.28%ClosedNov 6 '26